FDA staff finds Intercept's liver drug effective as monotherapy

The U.S. Food and Drug Administration's staff reviewers on Tuesday supported the use of Intercept Pharmaceuticals Inc's liver drug as a monotherapy in patients who did not respond to standard-of-care treatment.

http://ift.tt/xePdMM

from Reuters: Health News
via animenewspro